| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today that preliminary results from the SAVE Surveillance Registry will be presented by SeaStar Medical and its research collaborators at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Registry presentation will highlight the role of QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT). Safety data will also be presented.
A second accepted abstract will also be presented and include details of the SAVE Registry study design. It will be presented concurrent with the SAVE Registry data on Saturday, September 27, 2025, 6:20 – 8:00 pm Eastern Time. The presentations are as follows:
The SAVE Surveillance Registry is a Real-World Evidence (RWE) surveillance program that is designed to confirm safety and efficacy of the QUELIMMUNE therapy. Medical institutions employing the QUELIMMUNE therapy will continue to collect RWE for up to the first 300 patients treated with QUELIMMUNE. Specific outcomes data will include 90-day survival and dialysis dependency along with safety data with plans to compare to an existing control group of patients with similar severity of illness. SeaStar Medical believes that initial results from the SAVE Surveillance Registry will support broader adoption of the QUELIMMUNE therapy, inform payer discussions, and complement the company's ongoing effort to recruit patients into its adult NEUTRALIZE-AKI pivotal trial.
Posted In: ICU
